Alumis vs Palatin Technologies
ALMS and PTN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and PTN compare
Alumis is the larger company, worth 65 times as much as Palatin Technologies ($725M against $11.1M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | PTN |
|---|---|---|
| Size and price | ||
| Market cap | $725M | $11.1M |
| Share price | $5.60 | $6.23 |
| Change, 1 year | 6.9% | −43.6% |
| Change, 5 years | – | −98.6% |
| Beta (5Y) | −1.12 | 0.77 |
| Employees | 224 | 25 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 100× | – |
| P/B | 1.9× | 1.7× (better) |
| FCF yield | −44.3% (better) | −122% |
| Profitability | ||
| Operating margin | −6117% | – |
| Net margin | −5845% | – |
| FCF margin | −4433% | – |
| Return on equity | −111% (better) | −878% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −1288.8× |
| Current ratio | 5.57 (better) | 4.61 |
| Altman Z-score | −1.67 (better) | −75.61 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −152% |
| Shareholder yield | 0.00% (better) | −152% |
| Ownership | ||
| Held by institutions | 91.3% | 38.5% |
| Held by insiders | 30.5% | 20.6% |
| Insider net buying, 12 months | $44.7M (better) | −$9.5K |
| Short interest, % of float | 12.3% | 20.9% |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- PTN stock overview
- PTN income statement
- PTN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.